EIF2AK3 and ovarian carcinoma: Consistent with our previous findings using SpiD7 in ovarian cancer models (10), SpiD3 treatment activated sustained UPR signaling in CLL cells evidenced by an accumulation of unfolded proteins, PERK activation, and increased expression of ATF4, CHOP, and spliced XBP1.